ABSTRACT

Background: An oesophageal condition known as gastroesophageal reflux disease is characterised by a back flow of acid from the stomach and other gastric fluid into the oesophagus, which can irritate and inflame the tissue. The pathophysiology of the GERD continues to remain slightly misunderstood, but it’s now considered to be a multifactorial disease. H2 agonists as well proton pump inhibitors are two common medications used for the management of GERD disease. There are some well-known clinical agents including Pantoprazole and a prokeinetic agents like Itopride Hydrochloride that are prescribed to treat the GERD patients to prevent the disease progression and for prophylaxis as well. as Pantoprazole inhibits gastric acid and basal acid secretion by linking covalently to the H+/K+ ATP pump in the stomach's digestive parietal cell. Dopamine D2 receptor antagonist and acetylcholine esterase inhibitor itopride HCl is prescribed for the treatment of functional dyspepsia symptoms as well as those associated with other gastroesophageal diseases. This study shows the drug utilization pattern for the GERD disease treatment with the use of Pantoprazole monotherapy in comparison with itopride Hydrochloride combination therapy to see which is the better approach in the treatment of the patients, keeping in mind the cost of the drugs given to the patients. Objective: To estimate utilization and prescribing trends of pantoprazole agents alone and it’s combination with itopride in gastroesophageal reflux disease. To determine the cost analysis of combination therapy (pantoprazole+itopride) in GERD patients. To determine if pantoprazole and its combination provides maximum clinical benefits and minimum risks to the patients. Materials and Methods: It is a retrospective observational study conducted at a single centre done by obtaining the data of the patients receiving PPI agents and prokinetic agents for the treatment of the GERD. Drugs utilization evaluation and cost analysis of Pantoprazole and Itopride Hydrochloride is done. Total 100 patients’ data was collected and observed from Parul sevashram Hospital. In the data collection analysis form, the data was reported and analysed using graphical, chart, figures and tabulations and summarised visually. Unpaired t-test, chi- square, and an analysis of variance (ANOVA) were used in MS-Excel's statistical analysis, and the p-value was calculated. Results: Total out of 100 patient’s data 50 were prescribed with pantoprazole and 50 were prescribed with pantoprazole and itopride combination in which 20% of participants showed recovery in less than a week, 37% in one to two weeks, 36% in two to four weeks, and 7% in four to six weeks. According to the recommended therapy, there were 64% male and 36% female participants. Conclusion: pantoprazole 40 mg and pantoprazole-itopride hcl 150 mg both drugs are showing same healing rate into this study. However more research and large sample size required for comparision of efficacy in both drugs. Keywords: GERD (gastroesophageal reflux disease), pantoprazole, pantoprazole-itopride hydrochloride, TLESR (transient LES relaxation), Reflux mechanism
Publication date: 01/02/2025

https://ijbpas.com/pdf/2025/February/MS_IJBPAS_2025_8698.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.2.8698